Summary
In a double-blind, 4-week, prospective, randomized multicenter (17 centers) study we checked on the efficacy, tolerability and safety of moclobemide (300–600 mg/d) compared to imipramine (100–200 mg/d) in parallel groups of patients with a Major Depressive Episode (DSM III).
The mean % reduction of the HAMD at the end of treatment was 51.7 in the moclobemide group and 52.1 in the imipramine group. The percentage of patients in whom efficacy was globally judged as “good” or “very good” was 62% in the moclobemide group and 60% in the imipramine group.
“Further Investigators”
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Angst J (1986) Allgemeine Aspekte zur Behandlung mit Antidepressiva. In: Schmid-Burgk W Koella W (Hrsg) Neue Aspekte der Therapie mit Antidepressiva. Fischer, Stuttgart New York.
Baumhackl U, Biziere K Fischbach R, Geretsegger Ch, Hebenstreit G, Radmayr E, Stabl M (1990) Efficacy and tolerability of moclobemide compared with imipramine in depressive disorder (DSM III): an Austrian double-blind, multicentre study. Br J Psychiatry 155 [Suppl] 6:78–83.
Davidson J, McCleod MN, Blum MR (1978) Acetylation phenotype, platelet monoamine oxidase inhibitor and the effectiveness of phenelzine in depression. Am J Psychiatry 135:467–469.
Hebenstreit GF (1988) Efficacy and safety of moclobemide compared to imipramine in patients with major depression: results of an Austrian multicenter double-blind trial. Neurologija 37 [Suppl] 1:25.
Hebenstreit GF, et al. (1990) Efficacy, safety and tolerability of moclobemide compared with imipramine in the treatment of major depressive disorder. WPA-Regional Symposium, book of abstracts, p 114.
Kline NS, Cooper TB (1980) Monoamine oxidase inhibitors as antidepressants. In: Hoffmeister F, Stille G (eds) Psychotropic agents, part I. Antipsychotics and antidepressants. Springer, Berlin Heidelberg New York, pp 369–397.
Paykel ES (1971) Classification of depressed patients: a cluster analysis derived grouping. Br J Psychiatry 188:275–288.
Robinson DS, Nies A, Ravaris CL, Ives JO, Bertlett D (1978) Clinical psycho-pharmacology of phenelzine: MAO activity and clinical response. In: Lipton MA, DiMascio A, Killam KF (eds) Psychopharmacology: a generation of progress. Raven Press, New York.
West ED, Dally LJ (1959) Effects of iproniazid in depressive syndromes. Br Med J 1:1491–1494.
WHO Collaborative Study (1986) J Affect Dis 2:1–67.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1990 Springer-Verlag
About this paper
Cite this paper
Hebenstreit, G.F. et al. (1990). Efficacy and safety of moclobemide compared with imipramine in the treatment of major depressive disorder. Double-blind Multicenter Study, Austria. In: Riederer, P., Youdim, M.B.H. (eds) Amine Oxidases and Their Impact on Neurobiology. Journal of Neural Transmission, vol 32. Springer, Vienna. https://doi.org/10.1007/978-3-7091-9113-2_26
Download citation
DOI: https://doi.org/10.1007/978-3-7091-9113-2_26
Publisher Name: Springer, Vienna
Print ISBN: 978-3-211-82239-5
Online ISBN: 978-3-7091-9113-2
eBook Packages: Springer Book Archive